Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation

Mehdi Hamadani, Parameswaran N. Hari, Ying Zhang, Jeanette Carreras, Görgün Akpek, Mahmoud D. Aljurf, Ernesto Ayala, Veronika Bachanova, Andy Chen, Yi Bin Chen, Luciano J. Costa, Timothy S. Fenske, César O. Freytes, Siddhartha Ganguly, Mark S. Hertzberg, Leona A. Holmberg, David J. Inwards, Rammurti T. Kamble, Edward J. Kanfer, Hillard M. Lazarus & 13 others David I. Marks, Taiga Nishihori, Richard Olsson, Nishitha M. Reddy, David A. Rizzieri, Bipin N. Savani, Melhem Solh, Julie M. Vose, Baldeep Wirk, David G. Maloney, Sonali M. Smith, Silvia Montoto, Wael Saber

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The poor prognosis for patients with diffuse large Bcell lymphoma (DLBCL) who relapse within 1year of initial diagnosis after first-line rituximab-based chemo-immunotherapy has created controversy about the role of autologous transplantation (HCT) in this setting. We compared autologous HCT outcomes for chemosensitive DLBCL patients between 2000 and 2011 in 2 cohorts based on time to relapse from diagnosis. The early rituximab failure (ERF) cohort consisted of patients with primary refractory disease or those with first relapse within 1year of initial diagnosis. The ERF cohort was compared with those relapsing >1year after initial diagnosis (late rituximab failure [LRF] cohort). ERF and LRF cohorts included 300 and 216 patients, respectively. Nonrelapse mortality (NRM), progression/relapse, progression-free survival (PFS), and overall survival (OS) of ERF versus LRF cohorts at 3years were 9% (95% confidence interval [CI], 6% to 13%) versus 9% (95% CI, 5% to 13%), 47% (95% CI, 41% to 52%) versus 39% (95% CI, 33% to 46%), 44% (95% CI, 38% to 50%) versus 52% (95% CI, 45% to 59%), and 50% (95% CI, 44% to 56%) versus 67% (95% CI, 60% to 74%), respectively. On multivariate analysis, ERF was not associated with higher NRM (relative risk [RR], 1.31; P=34). The ERF cohort had a higher risk of treatment failure (progression/relapse or death) (RR, 2.08; P <.001) and overall mortality (RR, 3.75; P

Original languageEnglish (US)
Pages (from-to)1729-1736
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Medical Futility
Lymphoma, Large B-Cell, Diffuse
Cell Transplantation
Immunotherapy
Confidence Intervals
Recurrence
Mortality
Lymphoma
Rituximab
Autologous Transplantation
Delayed Diagnosis
Treatment Failure
Disease-Free Survival
Multivariate Analysis

Keywords

  • Aggressive lymphoma
  • Autologous transplantation
  • Diffuse large Bcell lymphoma
  • Early failure
  • High-dose therapy
  • Non-Hodgkin lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)

Cite this

Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. / Hamadani, Mehdi; Hari, Parameswaran N.; Zhang, Ying; Carreras, Jeanette; Akpek, Görgün; Aljurf, Mahmoud D.; Ayala, Ernesto; Bachanova, Veronika; Chen, Andy; Chen, Yi Bin; Costa, Luciano J.; Fenske, Timothy S.; Freytes, César O.; Ganguly, Siddhartha; Hertzberg, Mark S.; Holmberg, Leona A.; Inwards, David J.; Kamble, Rammurti T.; Kanfer, Edward J.; Lazarus, Hillard M.; Marks, David I.; Nishihori, Taiga; Olsson, Richard; Reddy, Nishitha M.; Rizzieri, David A.; Savani, Bipin N.; Solh, Melhem; Vose, Julie M.; Wirk, Baldeep; Maloney, David G.; Smith, Sonali M.; Montoto, Silvia; Saber, Wael.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 11, 01.11.2014, p. 1729-1736.

Research output: Contribution to journalArticle

Hamadani, M, Hari, PN, Zhang, Y, Carreras, J, Akpek, G, Aljurf, MD, Ayala, E, Bachanova, V, Chen, A, Chen, YB, Costa, LJ, Fenske, TS, Freytes, CO, Ganguly, S, Hertzberg, MS, Holmberg, LA, Inwards, DJ, Kamble, RT, Kanfer, EJ, Lazarus, HM, Marks, DI, Nishihori, T, Olsson, R, Reddy, NM, Rizzieri, DA, Savani, BN, Solh, M, Vose, JM, Wirk, B, Maloney, DG, Smith, SM, Montoto, S & Saber, W 2014, 'Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 20, no. 11, pp. 1729-1736. https://doi.org/10.1016/j.bbmt.2014.06.036
Hamadani, Mehdi ; Hari, Parameswaran N. ; Zhang, Ying ; Carreras, Jeanette ; Akpek, Görgün ; Aljurf, Mahmoud D. ; Ayala, Ernesto ; Bachanova, Veronika ; Chen, Andy ; Chen, Yi Bin ; Costa, Luciano J. ; Fenske, Timothy S. ; Freytes, César O. ; Ganguly, Siddhartha ; Hertzberg, Mark S. ; Holmberg, Leona A. ; Inwards, David J. ; Kamble, Rammurti T. ; Kanfer, Edward J. ; Lazarus, Hillard M. ; Marks, David I. ; Nishihori, Taiga ; Olsson, Richard ; Reddy, Nishitha M. ; Rizzieri, David A. ; Savani, Bipin N. ; Solh, Melhem ; Vose, Julie M. ; Wirk, Baldeep ; Maloney, David G. ; Smith, Sonali M. ; Montoto, Silvia ; Saber, Wael. / Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 11. pp. 1729-1736.
@article{3f221804d8294ec48b6d3774d403d1e8,
title = "Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation",
abstract = "The poor prognosis for patients with diffuse large Bcell lymphoma (DLBCL) who relapse within 1year of initial diagnosis after first-line rituximab-based chemo-immunotherapy has created controversy about the role of autologous transplantation (HCT) in this setting. We compared autologous HCT outcomes for chemosensitive DLBCL patients between 2000 and 2011 in 2 cohorts based on time to relapse from diagnosis. The early rituximab failure (ERF) cohort consisted of patients with primary refractory disease or those with first relapse within 1year of initial diagnosis. The ERF cohort was compared with those relapsing >1year after initial diagnosis (late rituximab failure [LRF] cohort). ERF and LRF cohorts included 300 and 216 patients, respectively. Nonrelapse mortality (NRM), progression/relapse, progression-free survival (PFS), and overall survival (OS) of ERF versus LRF cohorts at 3years were 9{\%} (95{\%} confidence interval [CI], 6{\%} to 13{\%}) versus 9{\%} (95{\%} CI, 5{\%} to 13{\%}), 47{\%} (95{\%} CI, 41{\%} to 52{\%}) versus 39{\%} (95{\%} CI, 33{\%} to 46{\%}), 44{\%} (95{\%} CI, 38{\%} to 50{\%}) versus 52{\%} (95{\%} CI, 45{\%} to 59{\%}), and 50{\%} (95{\%} CI, 44{\%} to 56{\%}) versus 67{\%} (95{\%} CI, 60{\%} to 74{\%}), respectively. On multivariate analysis, ERF was not associated with higher NRM (relative risk [RR], 1.31; P=34). The ERF cohort had a higher risk of treatment failure (progression/relapse or death) (RR, 2.08; P <.001) and overall mortality (RR, 3.75; P",
keywords = "Aggressive lymphoma, Autologous transplantation, Diffuse large Bcell lymphoma, Early failure, High-dose therapy, Non-Hodgkin lymphoma, Rituximab",
author = "Mehdi Hamadani and Hari, {Parameswaran N.} and Ying Zhang and Jeanette Carreras and G{\"o}rg{\"u}n Akpek and Aljurf, {Mahmoud D.} and Ernesto Ayala and Veronika Bachanova and Andy Chen and Chen, {Yi Bin} and Costa, {Luciano J.} and Fenske, {Timothy S.} and Freytes, {C{\'e}sar O.} and Siddhartha Ganguly and Hertzberg, {Mark S.} and Holmberg, {Leona A.} and Inwards, {David J.} and Kamble, {Rammurti T.} and Kanfer, {Edward J.} and Lazarus, {Hillard M.} and Marks, {David I.} and Taiga Nishihori and Richard Olsson and Reddy, {Nishitha M.} and Rizzieri, {David A.} and Savani, {Bipin N.} and Melhem Solh and Vose, {Julie M.} and Baldeep Wirk and Maloney, {David G.} and Smith, {Sonali M.} and Silvia Montoto and Wael Saber",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.bbmt.2014.06.036",
language = "English (US)",
volume = "20",
pages = "1729--1736",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation

AU - Hamadani, Mehdi

AU - Hari, Parameswaran N.

AU - Zhang, Ying

AU - Carreras, Jeanette

AU - Akpek, Görgün

AU - Aljurf, Mahmoud D.

AU - Ayala, Ernesto

AU - Bachanova, Veronika

AU - Chen, Andy

AU - Chen, Yi Bin

AU - Costa, Luciano J.

AU - Fenske, Timothy S.

AU - Freytes, César O.

AU - Ganguly, Siddhartha

AU - Hertzberg, Mark S.

AU - Holmberg, Leona A.

AU - Inwards, David J.

AU - Kamble, Rammurti T.

AU - Kanfer, Edward J.

AU - Lazarus, Hillard M.

AU - Marks, David I.

AU - Nishihori, Taiga

AU - Olsson, Richard

AU - Reddy, Nishitha M.

AU - Rizzieri, David A.

AU - Savani, Bipin N.

AU - Solh, Melhem

AU - Vose, Julie M.

AU - Wirk, Baldeep

AU - Maloney, David G.

AU - Smith, Sonali M.

AU - Montoto, Silvia

AU - Saber, Wael

PY - 2014/11/1

Y1 - 2014/11/1

N2 - The poor prognosis for patients with diffuse large Bcell lymphoma (DLBCL) who relapse within 1year of initial diagnosis after first-line rituximab-based chemo-immunotherapy has created controversy about the role of autologous transplantation (HCT) in this setting. We compared autologous HCT outcomes for chemosensitive DLBCL patients between 2000 and 2011 in 2 cohorts based on time to relapse from diagnosis. The early rituximab failure (ERF) cohort consisted of patients with primary refractory disease or those with first relapse within 1year of initial diagnosis. The ERF cohort was compared with those relapsing >1year after initial diagnosis (late rituximab failure [LRF] cohort). ERF and LRF cohorts included 300 and 216 patients, respectively. Nonrelapse mortality (NRM), progression/relapse, progression-free survival (PFS), and overall survival (OS) of ERF versus LRF cohorts at 3years were 9% (95% confidence interval [CI], 6% to 13%) versus 9% (95% CI, 5% to 13%), 47% (95% CI, 41% to 52%) versus 39% (95% CI, 33% to 46%), 44% (95% CI, 38% to 50%) versus 52% (95% CI, 45% to 59%), and 50% (95% CI, 44% to 56%) versus 67% (95% CI, 60% to 74%), respectively. On multivariate analysis, ERF was not associated with higher NRM (relative risk [RR], 1.31; P=34). The ERF cohort had a higher risk of treatment failure (progression/relapse or death) (RR, 2.08; P <.001) and overall mortality (RR, 3.75; P

AB - The poor prognosis for patients with diffuse large Bcell lymphoma (DLBCL) who relapse within 1year of initial diagnosis after first-line rituximab-based chemo-immunotherapy has created controversy about the role of autologous transplantation (HCT) in this setting. We compared autologous HCT outcomes for chemosensitive DLBCL patients between 2000 and 2011 in 2 cohorts based on time to relapse from diagnosis. The early rituximab failure (ERF) cohort consisted of patients with primary refractory disease or those with first relapse within 1year of initial diagnosis. The ERF cohort was compared with those relapsing >1year after initial diagnosis (late rituximab failure [LRF] cohort). ERF and LRF cohorts included 300 and 216 patients, respectively. Nonrelapse mortality (NRM), progression/relapse, progression-free survival (PFS), and overall survival (OS) of ERF versus LRF cohorts at 3years were 9% (95% confidence interval [CI], 6% to 13%) versus 9% (95% CI, 5% to 13%), 47% (95% CI, 41% to 52%) versus 39% (95% CI, 33% to 46%), 44% (95% CI, 38% to 50%) versus 52% (95% CI, 45% to 59%), and 50% (95% CI, 44% to 56%) versus 67% (95% CI, 60% to 74%), respectively. On multivariate analysis, ERF was not associated with higher NRM (relative risk [RR], 1.31; P=34). The ERF cohort had a higher risk of treatment failure (progression/relapse or death) (RR, 2.08; P <.001) and overall mortality (RR, 3.75; P

KW - Aggressive lymphoma

KW - Autologous transplantation

KW - Diffuse large Bcell lymphoma

KW - Early failure

KW - High-dose therapy

KW - Non-Hodgkin lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84908019168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908019168&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.06.036

DO - 10.1016/j.bbmt.2014.06.036

M3 - Article

VL - 20

SP - 1729

EP - 1736

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 11

ER -